BMPR2-E376K and ACVR1-R206H Mutations Enhance Osteogenic Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of Fibrodysplasia ossificans progressiva (FOP) is limited by the focus on ACVR1 mutations, with only 95% of cases attributed to the ACVR1-R206H mutation, and the molecular basis of how activin A enhances BMP signaling in these cases remains unclear, hindering effective treatment options.
Innovation Solution
Identification of a novel gain-of-function mutation in the BMPR2 gene, specifically the BMPR2-E376K mutation, which, when combined with the ACVR1-R206H mutation, enhances osteogenic differentiation and is used to treat bone diseases through induced pluripotent stem cells and mesenchymal stem cells, offering a new approach to understanding and addressing FOP-like phenotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If ACVR1-R206H mutation is used to treat bone diseases, then osteogenic differentiation is enhanced, but the molecular mechanism remains unclear and treatment options are limited
Solution Approach 1:
The patent combines ACVR1-R206H mutation with BMPR2-E376K mutation to create a dual-mutation system. This merging of two gain-of-function mutations synergistically enhances BMP signaling and osteogenic differentiation, while also providing a more complete molecular mechanism for understanding FOP pathogenesis and developing targeted therapies.
2Productivity
If BMPR2-E376K mutation is introduced to enhance BMP signaling, then osteogenic differentiation is improved, but heterotopic ossification occurs
Solution Approach 1:
The patent introduces specific amino acid substitutions (E376K in BMPR2 and R206H in ACVR1) that alter the functional parameters of these receptors. These parameter changes result in constitutive activation of BMP signaling, which enhances osteogenic differentiation but also leads to pathological heterotopic ossification, demonstrating a trade-off that must be managed in therapeutic applications.
3Device complexity
If focus is maintained on ACVR1 mutations, then FOP case understanding is simplified, but 5% of FOP cases without ACVR1 mutations remain unexplained
Solution Approach 1:
The patent identifies BMPR2 as an additional gene that can cause FOP-like phenotypes, expanding the diagnostic framework from ACVR1-only to include both ACVR1 and BMPR2. This universal approach ensures that both the 95% of cases with ACVR1 mutations and the 5% of cases with BMPR2 mutations can be accurately diagnosed and understood.
Data Source
AI summary
There is provided a mutation complex including: a BMPR2-E376K mutant in which an amino acid at position 376 of BMPR2 gene encoding a bone morphogenetic protein type 2 receptor (BMPR2) has mutated from glutamic acid (E) to lysine (K); and an ACVR1-R206H mutant in which an amino acid at position 206 of ACVR1 gene encoding an activin A type I receptor (ACVR1) has mutated from arginine (R) to histidine (H). There are also provided induced pluripotent stem cells reprogrammed from cells including the BMPR2-E376K mutant in which an amino acid at position 376 of BMPR2 gene encoding a bone morphogenetic protein type 2 receptor (BMPR2) has mutated from glutamic acid (E) to lysine (K).